Darunavir/Cobicistat (Prezcobix)
The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mu...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015 Jul, 2015
|
| Series: | Common drug review
|
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this systematic review is to examine the beneficial and harmful effects of cobicistat-boosted darunavir (DRV/COBI) 800 mg/150 mg for the treatment of HIV-1 infection in antiretroviral treatment-naive and treatment-experienced patients without darunavir (DRV) resistance-associated mutations (RAMs) |
|---|---|
| Physical Description: | 1 online resource illustrations |